var data={"title":"Sulfasalazine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfasalazine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6999?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">see &quot;Sulfasalazine: Drug information&quot;</a> and <a href=\"topic.htm?path=sulfasalazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sulfasalazine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223903\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azulfidine;</li>\n      <li>Azulfidine EN-tabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223904\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sulfasalazine;</li>\n      <li>PMS-Sulfasalazine;</li>\n      <li>Salazopyrin;</li>\n      <li>Salazopyrin En-Tabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050054\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">5-Aminosalicylic Acid Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050048\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">see &quot;Sulfasalazine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease (eg, ulcerative colitis; Crohn's disease):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Ulcerative colitis: Children &ge;6 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Induction: 40-60 mg/kg/day in 3-6 divided doses; maximum daily dose: 4000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: 30 mg/kg/day in 4 divided doses; maximum daily dose: 2000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing:  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Induction: Crohn disease, ulcerative colitis: 40-70 mg/kg/day in 4-6 divided doses; in some cases, higher induction doses up to 100 mg/kg/day may be required; maximum daily dose: 4000 mg/<b>day</b> (Rufo, 2012; Sandu, 2010; Turner, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: Ulcerative colitis: 30-70 mg/kg/day in 2-6 divided doses; maximum daily dose: 4000 mg/<b>day</b> (Sandu, 2010; Turner, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing  [Salazopyrin prescribing information (Canada), 2013]: Children &ge;25 kg and Adolescents: <b>Note:</b> Consider dose reduction or use of enteric coated tablet in patients experiencing adverse gastrointestinal effects with uncoated tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Acute attacks:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">25 to &lt;35 kg: 500 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">35-50 kg: 1000 mg 2-3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance of remission:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">25 to &lt;35 kg: 500 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">35-50 kg: 500 mg 2-3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desensitization regimen: Children &ge;6 years and Adolescents: For patients who may be sensitive to treatment, it is suggested to start with a total dose of 50-250 mg daily and double it every 4-7 days until the desired dose is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis:</b> Children and Adolescents 6-16 years: Oral: Enteric coated tablet: 30-50 mg/kg/day in 2 divided doses; maximum daily dose: 2000 mg/<b>day</b> (Beukelman, 2011); <b>Note:</b> Although it is an FDA-labeled indication, the use of sulfasalazine for treatment of JIA is not recommended (per manufacturer; Ringold, 2013). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Oral: Enteric coated tablet: Initial: 0.5-1 g daily; increase weekly to maintenance dose of 2 g daily in 2 divided doses; maximum: 3 g daily (if response to 2 g daily is inadequate after 12 weeks of treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 3-4 g daily in evenly divided doses at &le;8-hour intervals; may initiate therapy with 1-2 g daily to reduce GI intolerance. <b>Note:</b> American College of Gastroenterology guideline recommendations: Titrate to 4-6 g daily in 4 divided doses (Kornbluth, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 2 g daily in evenly divided doses at &le;8-hour intervals; if GI intolerance occurs reduce dosage by 50% and gradually increase to target dose after several days. If GI intolerance persists, stop drug for 5-7 days and reintroduce at a lower daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desensitization regimen: For patients who may be sensitive to treatment, it is suggested to start with a total dose of 50-250 mg daily and double it every 4-7 days until the desired dose is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223882\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine EN-tabs: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223868\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050058\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets should be administered in evenly divided doses, preferably after meals. Do not crush enteric coated tablets.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223899\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050057\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Treatment of mild to moderate ulcerative colitis, adjunct therapy for severe ulcerative colitis and prolongation of remission of ulcerative colitis episodes (FDA approved in ages &ge;6 years and adults)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enteric coated tablet: Management of ulcerative colitis (FDA approved in ages &ge;6 years and adults); treatment of juvenile idiopathic arthritis (JIA) in patients with an inadequate response to NSAIDs or salicylates (FDA approved in ages 6-16 years), and treatment of rheumatoid arthritis in an inadequate response to, or intolerance of, an adequate trial of full doses of one or more NSAIDs (FDA approved in adults); has also been used for induction therapy for Crohn&rsquo;s disease. <b>Note:</b> Although it is an FDA-labeled indication, the use of sulfasalazine for treatment of JIA is not recommended (per manufacturer; Ringold, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223953\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SulfaSALAzine may be confused with salsalate, sulfADIAZINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine may be confused with Augmentin, azaTHIOprine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223951\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, dyspepsia, gastric distress, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Oligospermia (reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Heinz body anemia, hemolytic anemia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cyanosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening (includes reactions reported with mesalamine or other sulfonamides): Agranulocytosis, alopecia, anaphylaxis, angioedema, aplastic anemia, arthralgia, cauda equina syndrome, cholestatic hepatitis, cholestatic jaundice, conjunctival injection, crystalluria, depression, diarrhea, DRESS syndrome, drowsiness, eosinophilia, exfoliative dermatitis, folate deficiency, fulminant hepatitis, Guillain-Barr&eacute; syndrome, hallucination, hearing loss, hematologic abnormality, hematologic disease (pseudomononucleosis), hematuria, hemolytic-uremic syndrome, hepatic cirrhosis, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hypoglycemia, hypoprothrombinemia, injected sclera, insomnia, interstitial nephritis, interstitial pulmonary disease, jaundice, Kawasaki syndrome (single case report), lupus-like syndrome, megaloblastic anemia, meningitis, methemoglobinemia, myelitis, myelodysplastic syndrome, myocarditis (allergic), nephritis, nephrolithiasis, nephrotic syndrome, neutropenia (congenital), neutropenic enterocolitis, oropharyngeal pain, pancreatitis, parapsoriasis varioliformis acuta, periarteritis nodosa, pericarditis, periorbital edema, peripheral neuropathy, pleurisy, pneumonia, pneumonitis, proteinuria, pulmonary alveolitis, purpura, renal disease (acute), rhabdomyolysis, seizure, sepsis, serum sickness-like reaction (children with JRA have frequent and severe reaction), skin discoloration, skin photosensitivity, Stevens-Johnson syndrome, thyroid function impairment, toxic epidermal necrolysis, toxic nephrosis, urine discoloration, vasculitis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223889\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sulfasalazine, its metabolites, sulfonamides, salicylates, or any component of the formulation; intestinal or urinary obstruction; porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &quot;Warnings/Precautions&quot; for more detail.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment; use in pediatric patients &lt;2 years of age; patients in whom acute asthmatic attacks, urticaria, rhinitis, or other allergic manifestations are precipitated by acetyl salicylic acid (ASA) or other NSAIDs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223872\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions, including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred; discontinue use at first sign of rash or signs of serious adverse reactions. The presence of clinical signs such as sore throat, fever, pallor, or purpura may be indicative of a serious blood disorder. Use with extreme caution in patients with blood dyscrasias; monitor CBC frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Deaths from irreversible neuromuscular and CNS changes have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe skin reactions (some fatal), including Stevens-Johnson syndrome (SJS), exfoliative dermatitis, and toxic epidermal necrolysis (TEN), have occurred with sulfonamides (including sulfasalazine), most commonly during the first month of treatment; discontinue use at first sign of skin rash, mucosal lesions, or any other sign of dermatologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fibrosing alveolitis: Deaths from fibrosing alveolitis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Folate deficiency: May decrease folic acid absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Nausea, vomiting, and abdominal discomfort commonly occur; titration of dose and/or using the enteric coated formulation may decrease GI adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic necrosis: Fatalities associated with hepatic damage have occurred; discontinue use at first sign of jaundice or hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe and life-threatening reactions, including drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, have been reported. Fever or lymphadenopathy may be present prior to rash development. Other severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome, hematologic abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration. Discontinue treatment for severe reactions and evaluate promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious infections (some fatal), including sepsis and pneumonia, have been reported. Infections may be associated with agranulocytosis, neutropenia, or myelosuppression. Monitor for signs/symptoms of infection during and after sulfasalazine therapy and promptly evaluate if infection occurs; discontinue therapy for serious infections. Use cautiously in patients with a history of recurring or chronic infections or with underlying conditions or concomitant therapy which may predispose them to infectious complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: In males, oligospermia (rare) and infertility have been reported; usually reverses upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&quot;sulfa&quot;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergies/asthma: Use with caution in patients with severe allergies or bronchial asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolytic anemia may occur (dose related).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with impaired hepatic function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with extreme caution in patients with renal impairment. Maintain adequate hydration to prevent crystalluria and stone formation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slow acetylators: Patients classified as slow acetylators may be at increased risk for adverse reactions due to a prolonged half-life of sulfapyrazine (metabolite of sulfasalazine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Delayed release: Use in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of GI intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites (eg, patients experiencing nausea and vomiting with the first few doses of the drug, patients in whom a reduction in dosage does not alleviate the adverse GI effects).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Enteric-coated tablets: Discontinue if tablets are noted to pass without disintegrating.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin/urine discoloration: May cause skin and urine discoloration (orange/yellow).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535483\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients treated with sulfasalazine for JIA have a high incidence of adverse events, including a serum-sickness-like reaction which presents with fever, nausea, vomiting, headache, rash, and altered LFTs; discontinue treatment if these occur; use of sulfasalazine for treatment of JIA is not recommended (per manufacturer; Ringold, 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300096\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223877\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12817&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Folic Acid: SulfaSALAzine may decrease the serum concentration of Folic Acid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: SulfaSALAzine may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: SulfaSALAzine may decrease the serum concentration of Methylfolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osimertinib: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: May increase the serum concentration of BCRP/ABCG2 Substrates. Management: Monitor patients receiving rolapitant for increased exposure to and/or effects of BCRP/ABCG2 substrates.  Use the lowest effective rosuvastatin dose when used in combination with rolapitant.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9751041\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfasalazine and sulfapyridine cross the placenta; a potential for kernicterus in the newborn exists. Agranulocytosis was noted in an infant following maternal use of sulfasalazine during pregnancy. Additionally, cases of neural tube defects have been reported (causation undetermined); sulfasalazine is known to inhibit the absorption and metabolism of folic acid and may diminish the effects of folic acid supplementation. Based on available data, an increase in fetal malformations has not been observed following maternal use of sulfasalazine for the treatment of inflammatory bowel disease or ulcerative colitis. When treatment for inflammatory bowel disease is needed during pregnancy, sulfasalazine may be used, although supplementation with folic acid is recommended (Habal 2012; Mahadevan 2009; Mottet 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050053\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, liver function tests (prior to therapy, then every other week for first 3 months of therapy, followed by every month for the second 3 months, then once every 3 months thereafter), urinalysis, renal function tests, liver function tests, stool frequency, hematocrit, reticulocyte count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223871\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223888\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Rheumatoid arthritis: &gt;4 weeks; Ulcerative colitis: &gt;3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Sulfasalazine: &lt;15% as parent drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Sulfasalazine: &gt;99% to albumin; Sulfapyridine: ~70% to albumin; Acetylsulfapyridine (AcSP): ~90% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Sulfasalazine: 7.5 &plusmn; 1.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Via colonic intestinal flora to sulfapyridine and 5-aminosalicylic acid (5-ASA). Following absorption, sulfapyridine undergoes acetylation to form AcSP and ring hydroxylation while 5-ASA undergoes N-acetylation (non-acetylation phenotype dependent process); rate of metabolism via acetylation dependent on acetylation phenotype</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Sulfasalazine: &lt;15%; Sulfapyridine: ~60%; 5-aminosalicylic acid: ~10% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Sulfasalazine: 7.6 &plusmn; 3.4 hours (prolonged in elderly patients); Sulfapyridine: 14.8 hours (slow acetylators) and 10.4 hours (fast acetylators)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Sulfasalazine: 3 to 12 hours (mean: 6 hours); Sulfapyridine and 5-aminosalicylic acid (5-ASA): ~10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (as unchanged drug, conjugates, and acetylated metabolites); feces (small amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10951003\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 100 mg/mL oral suspension may be made with tablets. Place twenty 500 mg tablets in a mortar and add a small amount of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; to cover the tablets. Let soak for 20-30 minutes. Crush the tablets and mix to a uniform paste; mix while adding the vehicle in equal proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label &quot;shake well&quot;. Stable 91 days under refrigeration or at room temperature.</p>\n    <div class=\"reference\">Lingertat-Walsh K, Walker SE, Law S, et al, &quot;Stability of Sulfasalazine Oral Suspension,&quot; <i>Can J Hosp Pharm</i>, 2006, 59(4):194-200.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223891\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Azulfidine EN-tabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $236.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (SulfaSALAzine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $43.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azulfidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $181.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SulfaSALAzine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $24.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223894\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Azulfidina (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Azulfidine (CL, DE, VE);</li>\n      <li>Azulfidine EN-tabs (AR);</li>\n      <li>Azulfidine-EN (CL);</li>\n      <li>Azulfin (BR);</li>\n      <li>Bomecon (TW);</li>\n      <li>Colo-Pleon (DE);</li>\n      <li>Disalazin (PE);</li>\n      <li>Falazine (EC);</li>\n      <li>Gastropyrin (FI);</li>\n      <li>Lazafin (ID);</li>\n      <li>Lazo (LK);</li>\n      <li>Pyralin EN (AU);</li>\n      <li>Rosulfant (CO);</li>\n      <li>SAAZ (IN);</li>\n      <li>Salazex (BD);</li>\n      <li>Salazine (TH, TW);</li>\n      <li>Salazo (BD);</li>\n      <li>Salazodin (UY);</li>\n      <li>Salazopirina (PT);</li>\n      <li>Salazopiryn EN (UA);</li>\n      <li>Salazopyrin (AE, AT, AU, BH, CH, CY, DK, EG, FI, GB, HN, HU, IE, IL, IQ, IR, IS, IT, JO, KW, LB, LV, LY, NZ, OM, PK, PL, QA, SA, SE, SY, TR, YE, ZA, ZW);</li>\n      <li>Salazopyrin EN (HR, MT, RO);</li>\n      <li>Salazopyrin Entabs (AE, BH, CY, DK, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salazopyrin-EN (AU, BG, CH, CO, CZ, EE, FI, GB, HK, IL, IT, MY, NO, NZ, SE, TH, TW, ZA);</li>\n      <li>Salazopyrina (ES);</li>\n      <li>Salazopyrine (BE, FR, LU, NL, VN);</li>\n      <li>Salazopyrine EC (BE);</li>\n      <li>Salivon (ID);</li>\n      <li>Salopyr (FI);</li>\n      <li>Salopyrine (GR);</li>\n      <li>Saridine-E (HK, TH);</li>\n      <li>Sazo (LK);</li>\n      <li>Sulcolon (ID);</li>\n      <li>Sulfasalazin (HR);</li>\n      <li>Sulfitis (ID);</li>\n      <li>Sulsa 500 (TH);</li>\n      <li>Sulzin (BD);</li>\n      <li>Zopyrin (HK, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care Res</i>. 2011;63(4):465-482. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/21452260/pubmed\" target=\"_blank\" id=\"21452260\">21452260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM, Huang VW. Review article: A decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. <i>Aliment Pharmacol Ther</i>. 2012;35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. <i>Am J Gastroenterol</i>. 2010;105(3):501-523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U. Pregnancy and inflammatory bowel disease. <i>Gastroenterol Clin North Am</i>. 2009;38(4):629-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/19913206/pubmed\" target=\"_blank\" id=\"19913206\">19913206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Juillerat P, Pittet V, et al. Pregnancy and breastfeeding in patients with Crohn's disease. <i>Digestion</i>. 2007;76(2):149-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/18239407/pubmed\" target=\"_blank\" id=\"18239407\">18239407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J  Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/22516861/pubmed\" target=\"_blank\" id=\"22516861\">22516861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JME, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>JPGN</i>. 2010;50:1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/20081543/pubmed\" target=\"_blank\" id=\"20081543\">20081543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher J, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutrit</i>. 2012;55(3):340-361. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-pediatric-drug-information/abstract-text/22773060/pubmed\" target=\"_blank\" id=\"22773060\">22773060</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12817 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223903\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223904\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050054\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050048\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223882\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223868\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050058\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F223899\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050057\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223953\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223951\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223889\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223872\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535483\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300096\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223877\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9751041\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050053\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223871\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223888\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10951003\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F223891\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223894\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12817|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">Sulfasalazine: Drug information</a></li><li><a href=\"topic.htm?path=sulfasalazine-patient-drug-information\" class=\"drug drug_patient\">Sulfasalazine: Patient drug information</a></li></ul></div></div>","javascript":null}